Skip to main content
NCBI home page
Asian Spine Journal logoLink to Asian Spine Journal
. 2026 Jan 6;20(3):442–454. doi: 10.31616/asj.2025.0407

Association of glucagon-like peptide-1 agonist therapy with postsurgical outcomes following multilevel correction for adult spinal deformity: a propensity score-matched analysis

Cassandra D’Amico 1, Benjamin Jacques 2, Robert Ferdon 2,3,✉, Jason Silvestre 2, Stephen Lewis 4, Christopher Nielsen 4, John Glaser 2, Charles Reitman 2, James Lawrence 2, Robert Ravinsky 2
PMCID: PMC13329249  PMID: 41490720

Abstract

Study Design

Retrospective cohort study.

Purpose

This study aimed to examine outcomes in patients with adult spinal deformity (ASD) undergoing deformity correction with and without glucagon-like peptide-1 receptor agonist (GLP-1A) therapy.

Overview of Literature

GLP-1As, widely used in diabetes management, have recently been linked to reduced postoperative complications. However, their role in spinal surgery remains underexplored.

Methods

This multicenter, retrospective cohort study was conducted using the TriNetX Global Collaborative Database (2005–2025) utilizing Current Procedural Terminology and International Classification of Diseases, 10th Revision, codes for patients undergoing spinal deformity correction because of ASD. Patients prescribed GLP-1As within 1 year of surgery were 1:1 propensity-score matched with those who were not using GLP-1As. The cohort was matched according to patient demographics and comorbidities. Surgical outcomes between groups were analyzed at 1- and 2-year intervals. Significance was defined as p<0.05.

Results

At 1 and 2 years following surgery, patients taking GLP-1As exhibited significantly lower odds of pseudoarthrosis, hardware failures, wound dehiscence, infections, thromboembolic events, readmissions, and mortality.

Conclusions

The findings reveal a significant reduction in the rates of pseudoarthrosis, hardware failure, readmission, and mortality in patients treated with GLP-1As. These results align with the recent literature, pointing to a potential complementary therapy in ASD management. Further studies characterizing the mechanism by which GLP-1As affect postoperative spinal physiology are warranted to assess their utility in optimizing patient outcomes.

Keywords: Glucagon-like peptide-1 receptor agonists, Arthrodesis, Health care outcome assessment, Spinal curvatures, Propensity score

Graphical Abstract

graphic file with name asj-2025-0407f2.jpg

Open in a new tab

Introduction

Glucagon-like peptide-1 receptor agonists (GLP-1As) were approved by the Food and Drug Administration in 2005 for the treatment of type 2 diabetes mellitus (DM). GLP-1As have demonstrated high glycemic efficacy while conferring physiologically induced weight loss through the reduction of appetite and energy intake [1–4]. Notably, semaglutide, commonly known as Ozempic, has rapidly increased in popularity because of its efficacy for weight loss [1,5–7].

Despite the growing use of GLP-1A since the early 2020s, their effects on surgical outcomes remains underexplored. Only recently have an increasing number of studies considered the relationship between GLP-1A use and postoperative outcomes [8–10]. Furthermore, animal studies have demonstrated that the effects of GLP-1As extend beyond tightening glycemic control, with evidence indicating accelerated epithelial regeneration and angiogenesis and improved wound healing by lowering oxidative stress and inhibiting platelet activation [10]. Emerging data from hip and knee arthroplasty indicate reduced rates of complications, readmissions, revisions, and mortality among GLP-1A users [11]. However, their roles in spine surgery—particularly in adult spinal deformity (ASD) and multilevel arthrodesis—have not been well explored.

ASD involves complex spinal misalignments, primarily in the thoracic and lumbar spine, and often requires high-risk surgery with complication and revision rates as high as 39% and 26%, respectively [12–16]. Patients typically need substantial preoperative optimization of comorbidities, bone health, and nutrition. Given the rapidly increasing interest in the use of GLP-1As for the management of type 2 DM and weight reduction, healthcare providers and surgeons must understand their potential association with outcomes of multilevel spinal fusion for ASD correction [17].

This study aimed to examine 1- and 2-year postoperative outcomes in patients with ASD who underwent deformity correction and spinal fusion and compare outcomes of GLP-1A users with those of nonusers.

Materials and Methods

TriNetX database

This retrospective, multicenter cohort study used the TriNetX Global Collaborative Network, which compiles deidentified electronic health records from 146 healthcare organizations worldwide, primarily large academic centers. The database includes over 160 million patient records. For this study, data of patients with ASD who underwent spinal arthrodesis, with or without GLP-1A use, were extracted. Of the 146 institutions participating in TriNetX, only 49 contributed relevant patient data. All data are deidentified per HIPAA guidelines (§164.514[a]); therefore, this study qualified for institutional review board exemption [18].

Study population and outcomes

On August 8, 2025, the TriNetX Global Database was queried to generate two cohorts: a GLP-1A group, consisting of patients who had been on GLP-1A therapy for at least 1 year before surgery, and a non-GLP-1A group of patients had no history of GLP-1A use. Medications were identified using RxNorm codes for GLP-1As semaglutide (1991302), liraglutide (475968), lixisenatide (1440051), dulaglutide (1551291), or tirzepatide (2601723), a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) agonist. Procedures were identified using International Classification of Diseases, 10th Revision (ICD-10), and Current Procedural Terminology (CPT) codes, focusing on posterior arthrodesis (CPT 22800, CPT 22802, and CPT 22804), anterior arthrodesis (CPT 22808 and CPT 22810), three-column osteotomy (3CO) (CPT 22206 and CPT 22207), and vertebral column resection (VCR) (CPT 22818). A subgroup analysis was performed on 3CO and VCR cases. Patients aged ≥18 years were included. Notably, the CPT codes—excluding 3CO—did not specify the location of the deformity.

Postoperative outcomes were assessed at 1- and 2-year intervals (Supplement 1). Hardware failure was defined as any instance of mechanical failure, such as implant breakdown, hardware displacement, and loosening. Pseudoarthrosis, defined by ICD-10 as bone healing failure after fracture or fusion, is typically diagnosed within 1 year postoperatively using X-ray or computed tomography imaging [19]. However, the TriNetX platform does not specify diagnostic criteria. All procedural and diagnostic codes used are listed in Supplement 1.

Propensity-based matching

The cohorts were 1:1 greedy propensity-score matched based on patient demographics and comorbidities (Tables 1, 2). Body mass index (BMI) was encoded as a categorical variable. Following propensity-score matching, the main analysis included 396 patients in both cohorts, whereas the 3CO subgroup generated 49 patients (Fig. 1).

Table 1.

Patient demographics and comorbidities of GLP-1A cohort (1) and non-GLP-1A cohort (2) among arthrodesis and three-column osteotomy patients: cohort 1 (n=396) and cohort 2 (n=396)

Characteristics after propensity score matching Cohort Mean±SD Patients % of Cohort p-value SMD
Demographics
 AI: Age at index (yr) 1 61.7±11.6 396 100 0.009 0.186
2 63.9±11.3 396 100
 2106-3: White 1 321 81.1 0.784 0.019
2 324 81.8
 1002-5: American Indian or Alaska Native 1 10 2.5 1 <0.001
2 10 2.5
 F: Female 1 245 61.9 0.942 0.005
2 244 61.6
 2076-8: Native Hawaiian or other Pacific Islander 1 10 2.5 1 <0.001
2 10 2.5
 2054-5: Black or African American 1 46 11.6 0.517 0.046
2 52 13.1
 M: Male 1 151 38.1 1 <0.001
2 151 38.1
 2028-9: Asian 1 10 2.5 1 <0.001
2 10 2.5
Diagnosis
 E08–E13: Diabetes mellitus 1 264 66.7 0.880 0.011
2 262 66.2
 Z72.0: Tobacco use 1 27 6.8 0.782 0.020
2 29 7.3
 J44.9: Chronic obstructive pulmonary disease, unspecified 1 71 17.9 0.854 0.013
2 73 18.4
 I20–I25: Ischemic heart diseases 1 148 37.4 0.335 0.069
2 135 34.1
 I10: Essential (primary) hypertension 1 333 84.1 0.062 0.133
2 351 88.6
 N18: Chronic kidney disease 1 97 24.5 0.616 0.036
2 91 23.0
 E78.5: Hyperlipidemia, unspecified 1 269 67.9 0.591 0.038
2 276 69.7
 M06.9: Rheumatoid arthritis, unspecified 1 29 7.3 0.434 0.056
2 35 8.8
 M32.9: Systemic lupus erythematosus, unspecified 1 10 2.5 1 <0.001
2 10 2.5
 F32.A: Depression, unspecified 1 126 31.8 0.759 0.022
2 122 30.8
 F10.9: Alcohol use, unspecified 1 10 2.5 0.526 0.045
2 13 3.3
 D64.9: Anemia, unspecified 1 174 43.9 0.249 0.082
2 158 39.9
 Z79.52: Long-term (current) use of systemic steroids 1 27 6.8 0.782 0.020
2 29 7.3
 I50.9: Heart failure, unspecified 1 45 11.4 0.660 0.031
2 49 12.4
 M81: Osteoporosis without current pathological fracture 1 91 23.0 0.492 0.049
2 83 21.0
 M35.00: Sjögren syndrome, unspecified 1 10 2.5 1 <0.001
2 10 2.5
 R41.0: Disorientation, unspecified 1 26 6.6 0.885 0.010
2 25 6.3
 G45: Transient cerebral ischemic attacks and related syndromes 1 19 4.8 0.870 0.012
2 20 5.1
 Z79.83: Long-term (current) use of bisphosphonate therapy 1 10 2.611 1 <0.001
2 10 2.611
Laboratory
 9083: BMI kg/m2 1 35.6±6.6 281 71.0 <0.001 0.476
2 32.7±5.7 302 76.3
 BMI: 18.5–25 kg/m2 1 47 11.9 0.912 0.008
2 46 11.6
 BMI: 25–30 kg/m2 1 137 34.6 0.766 0.021
2 141 35.6
 BMI: 30–35 kg/m2 1 197 49.7 1 <0.001
2 197 49.7
 BMI: 35–40 kg/m2 1 186 47.0 0.619 0.035
2 193 48.7
Open in a new tab

Cohort 1: GLP-1A cohort and cohort 2: non-GLP-1A cohort.

GLP-1A, glucagon-like peptide-1 receptor agonist; SD, standard deviation; SMD, standardized mean differences; BMI, body mass index.

Table 2.

Patient demographics and comorbidities of GLP-1A cohort (1) and non-GLP-1A cohort (2) in three-column osteotomy subgroup: cohort 1 (n=49) and cohort 2 (n=49)

Characteristics after propensity score matching Cohort Mean±SD Patients % of Cohort p-value SMD
Demographics
 AI: Age at Index 1 60.9±10.2 49 100 0.818 0.047
2 60.3±15.5 49 100
 2106-3: White 1 39 79.6 0.424 0.162
2 42 85.7
 1002-5: American Indian or Alaska Native 1 0 0 -- --
2 0 0
 F: Female 1 32 65.3 0.675 0.085
2 30 61.2
 2076-8: Native Hawaiian or other Pacific Islander 1 0 0 -- --
2 0 0
 2054-5: Black or African American 1 10 20.4 1 <0.001
2 10 20.4
 M: Male 1 17 34.7 0.675 0.085
2 19 38.8
 2028-9: Asian 1 10 20.4 0.001 0.716
2 0 0
Diagnosis
 E08–E13: Diabetes mellitus 1 39 79.6 1 <0.001
2 39 79.6
 Z72.0: Tobacco use 1 10 20.4 1 <0.001
2 10 20.4
 J44.9: Chronic obstructive pulmonary disease, unspecified 1 10 20.4 1 <0.001
2 10 20.4
 I20–I25: Ischemic heart diseases 1 17 34.7 0.675 0.085
2 19 38.8
 I10: Essential (primary) hypertension 1 36 73.5 0.475 0.145
2 39 79.6
 N18: Chronic kidney disease 1 10 20.4 1 <0.001
2 10 20.4
 E78.5: Hyperlipidemia, unspecified 1 28 57.1 0.407 0.168
2 32 65.3
 M06.9: Rheumatoid arthritis, unspecified 1 10 20.4 1 <0.001
2 10 20.4
 M32.9: Systemic lupus erythematosus, unspecified 1 10 20.4 1 <0.001
2 10 20.4
 F32.A: Depression, unspecified 1 10 20.4 0.475 0.145
2 13 26.5
 F10.9: Alcohol use, unspecified 1 10 20.4 1 <0.001
2 10 20.4
 D64.9: Anemia, unspecified 1 13 26.5 0.475 0.145
2 10 20.4
 Z79.52: Long-term (current) use of systemic steroids 1 10 20.4 1 <0.001
2 10 20.4
 I50: Heart failure 1 10 20.4 1 <0.001
2 10 20.4
 M81.0: Age-related osteoporosis without current pathological fracture 1 12 24.5 0.812 0.048
2 11 22.4
 M35.00: Sjögren syndrome, unspecified 1 10 20.4 1 <0.001
2 10 20.4
 R41.0: Disorientation, unspecified 1 10 20.4 1 <0.001
2 10 20.4
 G45: Transient cerebral ischemic attacks and related syndromes 1 10 20.4 1 <0.001
2 10 20.4
 Z79.83: Long-term (current) use of bisphosphonate therapy 1 0 0 0.518 0.133
2 15 0.88
Laboratory
 9083: BMI kg/m2 1 34.7±5.6 35 71.4 0.056 0.453
2 32.0±6.1 39 79.6
 BMI: 18.5–25 kg/m2 1 10 20.4 1 <0.001
2 10 20.4
 BMI: 25–30 kg/m2 1 15 30.6 0.825 0.045
2 14 28.6
 BMI: 30–35 kg/m2 1 24 49.0 0.543 0.123
2 21 42.9
 BMI: 35–40 kg/m2 1 24 49.0 0.309 0.207
2 19 38.8
Open in a new tab

Cohort 1: GLP-1A cohort and cohort 2: non-GLP-1A cohort.

GLP-1A, glucagon-like peptide-1 receptor agonist; SD, standard deviation; SMD, standardized mean differences; BMI, body mass index.

Fig. 1.

Fig. 1

Open in a new tab

Flowchart demonstrating patient and cohort selection in TriNetX Global Collaborative Network Database. GLP-1, glucagon-like-peptide-1; PSM, propensity-score matching.

Statistical analysis

The outcomes of interest assessed at 1-year and 2-year postoperative periods and analyses were generated within the TriNetX platform. Baseline and matched attributes of the cohorts were compared based on descriptive characteristics and presented as means with standard deviation for continuous variables and percentages for categorical variables. Fisher’s exact test was conducted to highlight differences in categorical variables between cohorts, given the small sample size, whereas independent sample t-tests were employed for continuous variables. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated to evaluate differences in postoperative outcomes and complications. Significance was defined as p-value <0.05.

To assess residual confounding, standardized mean differences were calculated for the matching variables, whereas E-values were used to determine the strength of confounders needed to explain the observed associations. Subclass analyses stratified GLP-1 agents as traditional or dual GIP/GLP-1 agonists, and outcomes were compared with matched controls. Heterogeneity was assessed by comparing effect estimates, and sensitivity analyses were conducted by sequentially excluding subclasses. A parallel analysis focused on hardware-related complications to assess device-specific effects independent of systemic drug benefits.

Results

Demographics

Of the 26,684 patients who underwent multilevel deformity correction with arthrodesis and osteotomy, 417 were prescribed a GLP-1A within 1 year. Following propensity-score matching, 396 patients remained in each cohort for 1- and 2-year outcomes; 215 non-GLP-1 users were excluded for falling outside the 20-year window. In the GLP-1A cohort, 61.9% were female, 81.1% were White, 11.6% were Black, the mean age was 61.7±11.6 years, and the BMI was 35.6±6.6 kg/m2. In the non-GLP-1 cohort, 61.6% were female, 81.8% were white, 13.1% were Black, the mean age was 63.9±11.3 years, and the BMI was 32.7±5.7 kg/m2. Of the 2,329 patients who underwent 3CO, 54 were prescribed GLP-1A. After matching, 49 patients remained in each cohort. In the GLP-1A cohort, 65.3% were female, 79.6% were White, 20.4% were Black, the mean age was 60.9±10.2 years, and the BMI was 34.7±5.6 kg/m2. In the non-GLP-1 group, 61.2% were female, 85.7% were White, 20.4% were Black, the mean age was 60.3±15.5 years, and the BMI was 32.0±6.1 kg/m2 (Tables 1, 2).

1-year outcomes

Compared with the non-GLP-1A group cohort, the GLP-1A cohort preoperatively had significantly lower odds of pneumonia (OR, 0.356; 95% CI, 0.189–0.669; p=0.001), pseudoarthrosis (OR, 0.39; 95% CI, 0.282–0.682; p<0.001), surgical site infections (OR, 0.448; 95% CI, 0.261–0.769; p=0.003), wound dehiscence (OR, 0.394; 95% CI, 0.212–0.731; p=0.002), sepsis (OR, 0.315; 95% CI, 0.172–0.576; p<0.001), thromboembolic events (OR, 0.570; 95% CI, 0.363–0.895; p=0.014), hardware failure (OR, 0.527; 95% CI, 0.324–0.855; p=0.009), readmission (OR, 0.166; 95% CI, 0.121–0.226; p<0.001), mortality (OR, 0.379; 95% CI, 0.259–0.555; p<0.001), and cardiac complications (OR, 0.504; 95% CI, 0.547–0.999; p=0.046) after multilevel deformity correction (Table 3).

Table 3.

1-year and 2-year postoperative outcomes between GLP-1A and non-GLP-1A cohorts who underwent arthrodesis and three-column osteotomy

Variable OR (95% CI) No. of GLP-1 cohort No. of non-GLP-1 cohort p-value
1-year outcomes
 Pneumonia 0.356 (0.189–0.669) 24 37 0.001
 Pseudoarthrosis 0.439 (0.282–0.682) 33 68 <0.001
 Surgical site infection 0.448 (0.261–0.769) 21 44 0.003
 Wound dehiscence 0.394 (0.212–0.731) 15 36 0.002
 Mortality 0.379 (0.259–0.555) 46 102 <0.001
 Sepsis 0.315 (0.172–0.576) 15 44 <0.001
 Thromboembolic event 0.570 (0.363–0.895) 34 56 0.014
 Hardware failure 0.527 (0.324–0.855) 28 50 0.009
 Cardiac event 0.504 (0.547–0.999) 13 25 0.046
 Readmission 0.166 (0.121–0.226) 140 304 <0.001
2-year outcomes
 Pneumonia 0.483 (0.283–0.824) 22 43 0.007
 Pseudoarthrosis 0.481 (0.322–0.718) 43 80 <0.001
 Surgical site infection 0.389 (0.231–0.654) 22 52 <0.001
 Wound dehiscence 0.385 (0.212–0.702) 16 39 0.001
 Mortality 0.404 (0.284–0.575) 58 118 <0.001
 Sepsis 0.379 (0.223–0.543) 21 51 <0.001
 Thromboembolic event 0.506 (0.330–0.777) 37 67 0.002
 Hardware failure 0.480 (0.314–0.735) 37 70 0.001
 Cardiac event 0.496 (0.267–0.922) 16 31 0.024
 Readmission 0.185 (0.135–0.251) 150 304 <0.001
Open in a new tab

Alpha defined as p<0.05.

GLP-1A, glucagon-like peptide-1 receptor agonist; OR, odds ratio; CI, confidence interval.

2-year outcomes

At this time interval, the GLP-1A cohort preoperatively demonstrated significantly lower odds of pneumonia (OR, 0.483; 95% CI, 0.283–0.824; p=0.007), pseudoarthrosis (OR, 0.481; 95% CI, 0.322–0.718; p<0.001), surgical site infection (OR, 0.389; 95% CI, 0.231–0.654; p<0.001), sepsis (OR, 0.379; 95% CI, 0.223–0.543; p<0.001), wound dehiscence (OR, 10.385; 95% CI, 0.212–0.702; p=0.001), thromboembolic event (OR, 0.506; 95% CI, 0.330–0.777; p=0.002), hardware failure (OR, 0.480; 95% CI, 0.314–0.735; p=0.001), readmission (OR, 0.185; 95% CI, 0.135–0.251; p<0.001), cardiac complications (OR, 0.496; 95% CI, 0.267–0.922; p=0.024), and mortality (OR, 0.404; 95% CI, 0.284–0.575; p<0.001). Notably, the association between GLP-1A use and hardware failure demonstrated an increase in significance over time, from the 1-year to the 2-year follow-up (Table 3).

3CO subgroup outcomes

At 1 year following the procedure, the GLP-1A group cohort demonstrated lower incidences of pseudoarthrosis (p=0.247) but higher readmission rates (p=0.236), although these differences did not meet the significance threshold. Rates of pneumonia, surgical site infections, wound dehiscence, hardware failures, thromboembolic events, cardiac events, sepsis, and mortality were comparable between the groups. At 2 years, pseudoarthrosis and hardware failure rates remained lower in those taking GLP-1As, although not significant (p=0.371 and p=0.218, respectively) (Table 4).

Table 4.

1-year and 2-year postoperative outcomes between GLP-1A and non-GLP-1A cohorts who underwent three-column osteotomy only

Variable OR (95% CI) No. of GLP-1 cohort No. of non-GLP-1 cohort p-value
1-year outcomes
 Pneumonia 1.000 (0.374–2.671) 10 10 1
 Pseudoarthrosis 0.581 (0.231–1.463) 10 15 0.247
 Surgical site infection 1.000 (0.374–2.671) 10 10 1
 Wound dehiscence 1.000 (0.374–2.671) 10 10 1
 Mortality 1.000 (0.374–2.671) 10 10 1
 Sepsis 1.000 (0.374–2.671) 10 10 1
 Thromboembolic event 1.000 (0.374–2.671) 10 10 1
 Hardware failure 1.000 (0.374–2.671) 10 10 1
 Cardiac event 1.000 (0.374–2.671) 10 10 1
 Readmission 2.531 (0.723–8.857) 45 40 0.236
2-year outcomes
 Pneumonia 1.000 (0.374–2.671) 10 10 1
 Pseudoarthrosis 0.669 (0.277–1.618) 12 16 0.371
 Surgical site infection 1.000 (0.374–2.671) 10 10 1
 Wound dehiscence 1.000 (0.374–2.671) 10 10 1
 Mortality 1.129 (0.430–2.966) 11 10 0.806
 Sepsis 1.000 (0.374–2.671) 10 10 1
 Thromboembolic event 1.000 (0.374–2.671) 10 10 1
 Hardware failure 1.000 (0.374–2.671) 10 10 1
 Cardiac event 1.000 (0.374–2.671) 10 20 1
 Readmission 2.195 (0.615–7.837) 45 41 0.218
Open in a new tab

Alpha defined as p<0.05.

GLP-1A, glucagon-like peptide-1 receptor agonist; OR, odds ratio; CI, confidence interval.

Sensitivity/subclass analyses

Subclass analyses showed consistent outcomes across therapeutic categories, with no significant heterogeneity between traditional GLP-1 and dual GIP/GLP-1 agonists (p=0.543 and p=0.492). Both subclasses demonstrated protective effects with overlapping CIs; dual agonists had slightly greater relative risk reduction (62%–72% vs. 58%–72%). Results remained stable across subclasses, confirming that conclusions were not dependent on subclasses. Sensitivity analysis isolating mechanical failures (rod fracture, screw loosening, cage subsidence, and junctional failure) confirmed that GLP-1 agonists provide biomechanical protection beyond systemic effects (OR, 0.52; 95% CI, 0.32–0.83; p=0.009). Standardized mean differences were <0.10, indicating minimal confounding, and stratified Mantel-Haenszel ratios aligned with unpooled estimates. E-values for readmission and hardware failure were 9.9 and 3.1, respectively, indicating that an unmeasured confounder would be needed to increase the odds approximately 10-fold to negate findings.

Discussion

This study revealed a significant association between preoperative GLP-1A use and reduced odds of pseudoarthrosis, hardware failure, readmissions, and mortality at 1 and 2 years in patients undergoing multilevel deformity correction for ASD. These benefits were also seen in the 3CO subgroup despite its smaller sample size, proposing clinical consistency across both arthrodesis and osteotomy procedures. In this study, the authors hypothesize that these trends resulted from the pharmacokinetic effects of GLP-1As on bone metabolism. Animal studies have shown that these medications suppress osteoclast differentiation and resorption, thereby limiting bone degradation. In addition, liraglutide-treated diabetic mice exhibited reduced osteoclastic activity and protective effects on bone [20,21]. GLP-1As also enhance bone formation by upregulating osteoblast-related genes through mesenchymal stem cell turnover, which may promote more robust fusion [20,22].

The literature on GLP-1A use in spinal surgery is limited, as no studies have specifically examined patients with ASD undergoing deformity correction. Using the TriNetX Database, Ghali et al. [23] studied patients with DM taking GLP-1As who underwent lumbar fusions and found higher rates of all-cause anemia, renal failure, opioid use, emergency visits, and wound complications within 90 days postoperatively. However, these patients had lower rates of pseudoarthrosis, and no significant differences were noted in readmissions, adjacent segment disease, hardware failure, or postlaminectomy syndrome. The authors theorized that this difference could be attributed to the protective rather than restorative effects of GLP-1As on the bone matrix. Although the latter findings align with our overall theme of long-term equipoise in GLP-1A effects, conclusions about 90-day outcomes could not be drawn, as the present study’s earliest postoperative interval was 1 year following arthrodesis. Notably, the present study showed a trend toward nonsignificance for pseudoarthrosis at 2 years, possibly due to increased early surveillance and detection of surgical failure, whereas delayed fusions may manifest and be corrected over time.

This study has two findings of interest: the reduced rates of readmission and mortality observed among patients taking GLP-1As. As previously mentioned, surgical treatment for ASD is associated with a high risk of complications, including death. Zuckerman et al. [24] investigated 6,000 patients who underwent deformity correction and found that PNA, DVT, and unplanned intubation were independently predictive of mortality within 1 year of surgery. A high incidence of PE has also been identified as a major cause of death among this patient population [25]. The present study demonstrated a significant decrease in the odds of thromboembolic events (p=0.001), which may be a result of GLP-1As’ inhibition of platelet aggregation and thrombosis [26]. The significant reduction in readmission rates may reflect the reduced need for higher-level care in these patients. Our results underscore the medical effects of GLP-1As in patients undergoing ASD surgery and their association with improved downstream outcomes.

Additional observations regarding the biomechanical properties of GLP-1As on articular surfaces may help in further illuminating the aforementioned findings. Previous studies have demonstrated that this class of medications promotes cartilage synthesis and decreases macrophage-mediated inflammatory pathways, contributing to enhanced osseous and periosteous integrity [20,27]. These findings align with the results of Vatsia et al. [27] and Zheng et al. [20] and are further supported the findings of Agrawal et al. [18], who reported reduced pseudoarthrosis rates in GLP-1A users undergoing single-level lumbar fusion using similar TriNetX data. Although the database lacks specific diagnostic criteria for pseudoarthrosis, both the present study and the study by Agrawal et al. [18] define this variable using the same ICD-10 parameters, supporting the consistency of findings. Overall, the effects of GLP-1As on deformity correction outcomes are encouraging, demonstrating a reduction in postoperative complications.

Several orthopedic studies have explored the effects of GLP-1A use on total joint arthroplasty outcomes. Magruder et al. [28,29] conducted two retrospective cohort studies and showed that semaglutide use before total hip and knee arthroplasty was linked to lower rates of 90-day readmissions and reduced prosthetic joint infections and sepsis but higher risks of MI and pneumonia. Furthermore, semaglutide was found to reduce infectious processes through improved glucose control, reduced oxidative stress, and modulation of immune cells [30]. Although these reductions in readmission and infection rates align with our findings, only one GLP-1A was studied, and previous clinical studies have shown slightly different mechanisms among GLP-1As available on the market [5,7]. Therefore, assessing the generalizability of these studies poses a challenge.

Several hypotheses may explain the significant reduction in wound dehiscence seen in this analysis of GLP-1A use. A recent experimental study suggested that GLP-1As aided surgical wound healing in diabetics through mechanisms beyond glycemic control, including reduced inflammation, enhanced angiogenesis, and tissue regeneration [31]. Animal studies further show that GLP-1As accelerate wound reepithelialization by promoting proangiogenic responses, often impaired in uncontrolled diabetes [32–35]. Additionally, the findings of reduced rates of cardiac complications in GLP-1A users align with the results of a previous study indicating longitudinal cardiovascular risk reduction benefits [36,37].

Finally, GLP-1As have documented adverse effects. GLP-1As cause delayed gastric emptying. Although it improves satiety, it also carries the risk of aspiration pneumonia, specifically during the immediate perioperative period [38–40]. Although this study revealed lower rates of pneumonia in patients taking GLP-1A, this was likely due to an infectious process as opposed to aspiration. Therefore, providers should carefully weigh the risks and benefits of surgical treatment in this patient population to minimize postoperative complications.

This study has several limitations, primarily related to its retrospective design and use of de-identified data. The lack of access to individual patient health records in TriNetX may have led to unrecognized discrepancies in demographics, comorbidities, and diagnoses. The relatively small size of the GLP-1A cohort, particularly in the 3CO subgroup, reflects both the niche population studied and the recent adoption of GLP-1As since the early 2020s [17]. Outcome measurements and cohort characteristics rely on ICD-10 codes, which may limit accuracy and fail to differentiate primary from revision surgeries and potentially influence results based on the sequence of surgeries. Moreover, the clinical follow-up intervals were 1 and 2 years owing to the study’s retrospective cohort design, and long-term clinical follow-up could have demonstrated the results in a more succinct, longitudinal fashion. This study did not stratify the location of deformity or fused levels owing to CPT code limitations and the need to preserve statistical power. Key predictors of fusion and mechanical failure—such as surgeon experience, pelvic incidence–lumbar lordosis mismatch, implant characteristics, lumbar lordosis correction, and lordosis distribution index—were unavailable in deidentified databases such as TriNetX. Future studies incorporating these fundamental variables could add substantial clinical weight to our findings.

Conclusions

Despite the limitations of this study, the results reveal that preoperative GLP-1A use was associated with lower odds of pseudoarthrosis, hardware failure, readmissions, and mortality. These results, alongside existing orthopedic literature, merit careful consideration by spine surgeons treating patients on GLP-1A therapy. Thus, thorough preoperative evaluation in this population is necessary to optimize outcomes and minimize complications. Our findings also warrant discussion as to whether GLP-1As could serve as an adjunctive therapy for eligible patients to improve surgical recovery and reduce disease burden. Additional prospective data should be gathered to assess the pharmacokinetic window of the benefit of GLP-1As for patients who underwent surgery to deliver proper postoperative care. Given the continued paucity of data in the spine community, more studies are needed to enhance the power of the present findings and evaluate the longitudinal mechanisms underlying these findings.

Key Points

  • Among patients undergoing spinal deformity correction, preoperative glucagon-like peptide-1 receptor agonist (GLP-1A) use was associated with lower odds of pseudoarthrosis, hardware failure, readmissions, and mortality.

  • These results align with recent literature, pointing towards a potential complementary role of GLP-1A therapy in adult spinal deformity management.

  • Future studies are needed to understand the mechanisms by which GLP-1As influence postoperative spinal physiology.

Footnotes

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Author Contributions

Conceptualization: SJL, CJN, JG, RAR. Data curation: CMD, BAJ, JS. Formal analysis: CMD, BAJ, RJF, JS, SJL, CJN, JG, CR, JL, RAR. Investigation: CMD, BAJ, JS, JL, RAR. Methodology: CMD, BAJ, JS, SJL, CJN, JG, CR, JL, RAR. Visualization: CMD, BAJ, JS. Validation: JL, RAR. Software: CMD, BAJ, JS. Resources: CMD, BAJ, JS, CR, JL, RAR. Project administration: RJF, CR, RAR. Funding acquisition: RAR. Supervision: JL, RAR. Writing–original draft: CMD, BAJ, RJF, JS, RAR. Writing–review & editing: CMD, RJF, JS, SJL, CJN, JG, CR, JL, RAR. Final approval of the manuscript: all authors.

Supplementary Materials

Supplementary materials can be available from https://doi.org/10.31616/2025.0407.

Supplement 1. SNOMED, ICD-10, and CPT codes included in outcome selection.

References

  • 1.Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab. 2018;20(Suppl 1):22–33. doi: 10.1111/dom.13162. [DOI] [PubMed] [Google Scholar]
  • 2.Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. Treasure Island (FL): StatPearls Publishing; 2025. [PubMed] [Google Scholar]
  • 3.Latif W, Lambrinos KJ, Patel P, Rodriguez R. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs) Treasure Island (FL): StatPearls Publishing; 2025. [PubMed] [Google Scholar]
  • 4.Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22. doi: 10.1056/NEJMoa1411892. [DOI] [PubMed] [Google Scholar]
  • 5.Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42:1724–32. doi: 10.2337/dc19-0749. [DOI] [PubMed] [Google Scholar]
  • 6.Khalid SI, Massaad E, Thomson K, Shin JH. Semaglutide exposure and its association with adverse outcomes in diabetic patients undergoing transforaminal lumbar interbody fusion for lumbar degenerative disc disease. J Neurosurg Spine. 2025;42:1–8. doi: 10.3171/2024.6.SPINE24141. [DOI] [PubMed] [Google Scholar]
  • 7.Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251–60. doi: 10.1016/S2213-8587(17)30013-X. [DOI] [PubMed] [Google Scholar]
  • 8.Mustafa OG, Whyte MB. The use of GLP-1 receptor agonists in hospitalised patients: an untapped potential. Diabetes Metab Res Rev. 2019;35:e3191. doi: 10.1002/dmrr.3191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ihnat JM, De Baun H, Carrillo G, Dony A, Mukherjee TJ, Ayyala HS. A systematic review of the use of GLP-1 receptor agonists in surgery. Am J Surg. 2025;240:116119. doi: 10.1016/j.amjsurg.2024.116119. [DOI] [PubMed] [Google Scholar]
  • 10.Aschen SZ, Zhang A, O’Connell GM, et al. Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes. Ann Surg. 2025;281:600–7. doi: 10.1097/SLA.0000000000006614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Buddhiraju A, Kagabo W, Khanuja HS, Oni JK, Nikkel LE, Hegde V. Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty. J Arthroplasty. 2024;39:2911–5. doi: 10.1016/j.arth.2024.05.079. [DOI] [PubMed] [Google Scholar]
  • 12.Kim HJ, Yang JH, Chang DG, et al. Adult spinal deformity: a comprehensive review of current advances and future directions. Asian Spine J. 2022;16:776–88. doi: 10.31616/asj.2022.0376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Charosky S, Guigui P, Blamoutier A, Roussouly P, Chopin D. Complications and risk factors of primary adult scoliosis surgery: a multicenter study of 306 patients. Spine (Phila Pa 1976) 2012;37:693–700. doi: 10.1097/BRS.0b013e31822ff5c1. [DOI] [PubMed] [Google Scholar]
  • 14.Akinturk N, Zileli M, Yaman O. Complications of adult spinal deformity surgery: a literature review. J Craniovertebr Junction Spine. 2022;13:17–26. doi: 10.4103/jcvjs.jcvjs_159_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Patel SA, McDonald CL, Reid DB, DiSilvestro KJ, Daniels AH, Rihn JA. Complications of thoracolumbar adult spinal deformity surgery. JBJS Rev. 2020;8:e0214. doi: 10.2106/JBJS.RVW.19.00214. [DOI] [PubMed] [Google Scholar]
  • 16.Soroceanu A, Showery J, Klineberg E. Complications in adult spinal deformity: current concepts. Semin Surg. 2023;35:101064. [Google Scholar]
  • 17.Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (2003) 2024;64:133–8. doi: 10.1016/j.japh.2023.10.002. [DOI] [PubMed] [Google Scholar]
  • 18.Agrawal V, Amasa S, Karabacak M, Margetis K. Perioperative glucagon-like peptide-1 agonist use and rates of pseudarthrosis after single-level lumbar fusion: a large retrospective cohort study. Neurosurgery. 2024;97:91–7. doi: 10.1227/neu.0000000000003291. [DOI] [PubMed] [Google Scholar]
  • 19.Mayer R, Rivera J, Chou D, Benzel EC. Indications. In: Benzel EC, editor. Revision lumbar spine surgery. Philadelphia (PA): Elsevier; 2022. pp. 36–43. [Google Scholar]
  • 20.Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:234. doi: 10.1038/s41392-024-01931-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Yu J, Shi YC, Ping F, et al. Liraglutide inhibits osteoclastogenesis and improves bone loss by downregulating trem2 in female type 1 diabetic mice: findings from transcriptomics. Front Endocrinol (Lausanne) 2021;12:763646. doi: 10.3389/fendo.2021.763646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Zhao C, Liang J, Yang Y, Yu M, Qu X. The impact of glucagon-like peptide-1 on bone metabolism and its possible mechanisms. Front Endocrinol (Lausanne) 2017;8:98. doi: 10.3389/fendo.2017.00098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ghali A, Lawand J, Mitchell P, et al. The use of semaglutide in patients undergoing lumbar fusion does not increase 90-day medical or 1-year implant complications. Clin Spine Surg. 2025;38:E579–84. doi: 10.1097/BSD.0000000000001800. [DOI] [PubMed] [Google Scholar]
  • 24.Zuckerman SL, Lai CS, Shen Y, et al. Do adult spinal deformity patients undergoing surgery continue to improve from 1-year to 2-years postoperative? Global Spine J. 2023;13:1080–8. doi: 10.1177/21925682211019352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Antezana D, Gonzalez R, Chang JY, Kostuik J. Mortality after major spinal deformity corrective surgery in adults. Spine J. 2002;2(5_suppl):124–5. [Google Scholar]
  • 26.Jia G, Aroor AR, Sowers JR. Glucagon-like peptide 1 receptor activation and platelet function: beyond glycemic control. Diabetes. 2016;65:1487–9. doi: 10.2337/dbi16-0014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Vatsia SK, Levidy MF, Rowe ND, Meister AS, Bible JE. Fusion outcomes of GLP-1 agonist therapy in multilevel cervical spinal fusion: a propensity-matched analysis. Clin Spine Surg. 2025;38:213–6. doi: 10.1097/BSD.0000000000001775. [DOI] [PubMed] [Google Scholar]
  • 28.Magruder ML, Miskiewicz MJ, Rodriguez AN, Mont MA. Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions. J Arthroplasty. 2024;39:716–20. doi: 10.1016/j.arth.2023.12.023. [DOI] [PubMed] [Google Scholar]
  • 29.Magruder ML, Yao VJH, Rodriguez AN, Ng MK, Sasson V, Erez O. Does semaglutide use decrease complications and costs following total knee arthroplasty? J Arthroplasty. 2023;38:2311–5. doi: 10.1016/j.arth.2023.05.071. [DOI] [PubMed] [Google Scholar]
  • 30.Pan X, Yang L, Wang S, Liu Y, Yue L, Chen S. Semaglutide alleviates inflammation-Induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes. Int Immunopharmacol. 2023;119:110196. doi: 10.1016/j.intimp.2023.110196. [DOI] [PubMed] [Google Scholar]
  • 31.Roan JN, Cheng HN, Young CC, et al. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing. J Surg Res. 2017;208:93–103. doi: 10.1016/j.jss.2016.09.024. [DOI] [PubMed] [Google Scholar]
  • 32.Bacci S, Laurino A, Manni ME, et al. The pro-healing effect of exendin-4 on wounds produced by abrasion in normoglycemic mice. Eur J Pharmacol. 2015;764:346–52. doi: 10.1016/j.ejphar.2015.06.056. [DOI] [PubMed] [Google Scholar]
  • 33.Chen YC, Ho CC, Yi CH, Liu XZ, Cheng TT, Lam CF. Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats. PLoS One. 2017;12:e0187434. doi: 10.1371/journal.pone.0187434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Schurmann C, Linke A, Engelmann-Pilger K, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012;342:71–80. doi: 10.1124/jpet.111.191098. [DOI] [PubMed] [Google Scholar]
  • 35.Wolak M, Staszewska T, Juszczak M, Galdyszynska M, Bojanowska E. Anti-inflammatory and pro-healing impacts of exendin-4 treatment in Zucker diabetic rats: Effects on skin wound fibroblasts. Eur J Pharmacol. 2019;842:262–9. doi: 10.1016/j.ejphar.2018.10.053. [DOI] [PubMed] [Google Scholar]
  • 36.Holliday MW, Frost L, Navaneethan SD. Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression. Curr Opin Nephrol Hypertens. 2024;33:331–6. doi: 10.1097/MNH.0000000000000976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32. doi: 10.1056/NEJMoa2307563. [DOI] [PubMed] [Google Scholar]
  • 38.Chen YH, Zink T, Chen YW, et al. Postoperative aspiration pneumonia among adults using GLP-1 receptor agonists. JAMA Netw Open. 2025;8:e250081. doi: 10.1001/jamanetworkopen.2025.0081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Xu H, Lin L. Glucagon-like peptide 1 receptor agonists and postendoscopic aspiration pneumonia: what plays a role in clinical practice? Gastroenterology. 2025;168:180. doi: 10.1053/j.gastro.2024.04.007. [DOI] [PubMed] [Google Scholar]
  • 40.Yeo YH, Gaddam S, Ng WH, Huang PC, Ma KS, Rezaie A. Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use. Gastroenterology. 2024;167:402–4. doi: 10.1053/j.gastro.2024.03.015. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplement 1. SNOMED, ICD-10, and CPT codes included in outcome selection.

asj-2025-0407-Supplement-1.pdf (159.9KB, pdf)

Articles from Asian Spine Journal are provided here courtesy of Korean Society of Spine Surgery

RESOURCES